Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

TitleImmunogenicity of a Meningococcal B Vaccine during a University Outbreak.
Publication TypeJournal Article
Year of Publication2016
AuthorsBasta, NE, Mahmoud, AAF, Wolfson, J, Ploss, A, Heller, BL, Hanna, S, Johnsen, P, Izzo, R, Grenfell, BT, Findlow, J, Bai, X, Borrow, R
JournalN Engl J Med
Volume375
Issue3
Pagination220-8
Date Published2016 Jul 21
ISSN1533-4406
KeywordsAntibodies, Bacterial, Disease Outbreaks, Female, Humans, Male, Meningitis, Meningococcal, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, New Jersey, Seroepidemiologic Studies, United States, Universities, Young Adult
Abstract

Background In December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used before licensure on the basis of special consideration by the Food and Drug Administration to respond to an outbreak of Neisseria meningitidis B at a U.S. university. Data suggested that vaccination would control the outbreak because isolates expressed antigens that were closely related to the vaccine antigens (factor H-binding protein [fHbp] and neisserial heparin-binding antigen). We quantified the immune responses induced by 4CMenB during the outbreak. Methods We conducted a seroprevalence survey among students to assess vaccination status and collect serum specimens to quantify titers of serum bactericidal antibodies (SBA) with an assay that included human complement (hSBA). We compared the proportion of vaccinated and unvaccinated participants who were seropositive for the outbreak strain and for one closely related reference strain (44/76-SL, which included fHbp) and one mismatched reference strain (5/99, which included neisserial adhesin A), both of which were used in vaccine development. Seropositivity was defined as an hSBA titer of 4 or higher. Results Among the 499 participants who received two doses of the 4CMenB vaccine 10 weeks apart, 66.1% (95% confidence interval [CI], 61.8 to 70.3) were seropositive for the outbreak strain, although the geometric mean titer was low at 7.6 (95% CI, 6.7 to 8.5). Among a random subgroup of 61 vaccinees who also received two doses but did not have a detectable protective response to the outbreak strain, 86.9% (95% CI, 75.8 to 94.2) were seropositive for the 44/76-SL strain, for which there was a geometric mean titer of 17.4 (95% CI, 13.0 to 23.2), whereas 100% of these vaccinees (95% CI, 94.1 to 100) were seropositive for the 5/99 strain and had a higher geometric mean titer (256.3; 95% CI, 187.3 to 350.7). The response to the outbreak strain was moderately correlated with the response to the 44/76-SL strain (Pearson's correlation,0.64; P<0.001) but not with the response to the 5/99 strain (Pearson's correlation,-0.06; P=0.43). Conclusions Eight weeks after the second dose of the 4CMenB vaccine was administered, there was no evidence of an hSBA response against the outbreak strain in 33.9% of vaccinees, although no cases of meningococcal disease caused by N. meningitidis B were reported among vaccinated students. (Funded by Princeton University and others.).

DOI10.1056/NEJMoa1514866
Alternate JournalN. Engl. J. Med.
PubMed ID27468058
PubMed Central IDPMC4992664
Grant ListDP5 OD009162 / OD / NIH HHS / United States
1DP5OD009162 / OD / NIH HHS / United States